KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) Return on Capital Employed (2016 - 2026)

Emergent BioSolutions has reported Return on Capital Employed over the past 16 years, most recently at 5.18% for Q1 2026.

  • For Q1 2026, Return on Capital Employed rose 1279.0% year-over-year to 5.18%; the TTM value through Mar 2026 reached 5.18%, up 1279.0%, while the annual FY2025 figure was 8.19%, 1572.0% up from the prior year.
  • Return on Capital Employed for Q1 2026 was 5.18% at Emergent BioSolutions, down from 7.96% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 9.78% in Q1 2022 and troughed at 60.19% in Q4 2023.
  • A 5-year average of 13.66% and a median of 8.55% in 2024 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -6053bps in 2023 and later soared 5164bps in 2024.
  • Year by year, Return on Capital Employed stood at 9.43% in 2022, then plummeted by -538bps to 60.19% in 2023, then soared by 86bps to 8.55% in 2024, then soared by 193bps to 7.96% in 2025, then tumbled by -35bps to 5.18% in 2026.
  • Business Quant data shows Return on Capital Employed for EBS at 5.18% in Q1 2026, 7.96% in Q4 2025, and 9.1% in Q3 2025.